Conditions: Perennial Allergic Rhinitis
Keywords: perennial allergic rhinitis PAR
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 327
Healthy volunteers: no

Brief summary:
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to measure patient satisfaction with and preference of intranasal corticosteroids (INCS) for the treatment of allergic rhinitis (AR), is utilized in this study.

Detailed description:
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to measure patient satisfaction with and preference of intranasal corticosteroids (INCS) for the treatment of allergic rhinitis (AR), is utilized in this study.

Subjects will be randomized to 1 of 2 treatment sequences:

Sequence 1: Treatment Period 1 = ciclesonide nasal aerosol 74 mcg once daily for two weeks; Treatment Period 2 = mometasone nasal inhalation 200 mcg once daily for two weeks Sequence 2: Treatment Period 1 = mometasone nasal inhalation 200 mcg once daily for two weeks; Treatment Period 2 = ciclesonide Nasal aerosol 74 mcg once daily for two weeks

Arms:
arm 1: 74 mcg ciclesonide nasal aerosol once daily arm 2: 200 mcg mometasone aqueous nasal spray once daily

Interventions: intervention 1: ciclesonide intervention 2: mometasone
Intervention descriptions: intervention 1: 74 mcg ciclesonide nasal aerosol once daily intervention 2: 200 mcg mometasone aqueous nasal spray once daily

Protocol document: